Molecular HIV screening.
Nuclear acid testing is more and more used for the diagnosis of infectious diseases. This paper focuses on the use of molecular tools for HIV screening. The term 'screening' will be used under the meaning of first-line HIV molecular techniques performed on a routine basis, which excludes HIV molecular tests designed to confirm or infirm a newly discovered HIV-seropositive patient or other molecular tests performed for the follow-up of HIV-infected patients. The following items are developed successively: i) presentation of the variety of molecular tools used for molecular HIV screening, ii) use of HIV molecular tools for the screening of blood products, iii) use of HIV molecular tools for the screening of organs and tissue from human origin, iv) use of HIV molecular tools in medically assisted procreation and v) use of HIV molecular tools in neonates from HIV-infected mothers.
Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP) - EA3064, Faculty of Medicine of Saint-Etienne, 42023, University of Lyon, France.
Thomas
T
Bourlet
Meriam
M
Memmi
Henia
H
Saoudin
Bruno
B
Pozzetto
D015658:HIV Infections / Q000097:blood / Q000175:diagnosis* / Q000635:transmission / Q000821:virology; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008403:Mass Screening / Q000295:instrumentation / Q000379:methods; D025202:Molecular Diagnostic Techniques; D019095:Point-of-Care Systems; D012367:RNA, Viral / Q000097:blood; D027724:Reproductive Techniques, Assisted; D019562:Viral Load
D012367:RNA, Viral